Dexoderm Cream

Quick links to important sections

Dexoderm Cream

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexoderm Cream

Quick Facts

Property Description
Active Ingredients Clobetasol Propionate, Ofloxacin, Ornidazole, Terbinafine Hydrochloride
Form Cream (Topical)
Pharmacological Class Potent Corticosteroid, Anti-infective Combination
General Purpose Simultaneous relief of inflammation and broad-spectrum microbial activity
Origin Synthetic
Differentiating Feature Contains four distinct agents, including an antiprotozoal component

Defining Dexoderm Cream: A Fixed-Dose Combination (FDC)

Dexoderm Cream is a synthetic, four-component Fixed-Dose Combination (FDC) preparation designed for Topical administration in a Cream dosage form. It is distinguished as a Topical Quadruple-Action Agent because it integrates four primary therapeutic agents into a single formulation. The FDC approach is recognized for offering convenience and broad target coverage in treating dermatological conditions, allowing for the concurrent application of multiple necessary agents instead of separate products.

Composition and Pharmacological Classes

The core of the medicine is defined by its four active ingredients (INN), each contributing to a distinct pharmacological class: Clobetasol Propionate (a potent Corticosteroid), Ofloxacin (a Fluoroquinolone Antibacterial), Ornidazole (a Nitroimidazole Antiprotozoal), and Terbinafine Hydrochloride (an Allylamine Antifungal). The inclusion of these four agents is a key differentiating factor, providing anti-inflammatory, antibacterial, antifungal, and antiprotozoal coverage. For instance, the general efficacy of allylamine agents against various dermatophyte fungi contributes to the functional profile of the composition.

General Purpose of this Multi-Action Topical Agent

The general purpose of this FDC is to achieve robust symptomatic relief from inflammation while providing simultaneous, broad-spectrum anti-infective coverage. This approach addresses the complexity of dermatological conditions where severe inflammation and a presumed polymicrobial infection are observed concurrently. The formulation is strategically designed to exert a synergistic effect against these dual pathologies, offering comprehensive action against both the body's over-response and underlying pathogenic growth.

Regulatory References

  1. Terbinafine - StatPearls - NCBI Bookshelf

What side effects are possible with Dexoderm Cream?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination cream reflects the potential adverse reactions associated with its four components, particularly the potent topical corticosteroid, Clobetasol Propionate. Official regulatory documents classify potential effects across several body systems.

Localized and Common Reactions

Adverse reactions classified as common are predominantly localized to the application site, including sensations of burning, stinging, pruritus (itching), erythema (redness), and irritation. Prolonged use is officially associated with local changes such as skin atrophy, striae (stretch marks), folliculitis, and telangiectasia.

Systemic Safety and Serious Adverse Reactions

Due to the potency of Clobetasol Propionate, there is a documented risk of systemic absorption, which may lead to Endocrine Disorders. This includes the potential for reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. Serious adverse reactions also include the potential for severe hypersensitivity reactions (such as anaphylaxis) related to the anti-infective components. Use near the eyes carries a specific risk for conditions like glaucoma.

Population-Specific Safety Considerations

Specific safety concerns are documented for pediatric patients, who are at an increased risk of systemic toxicity, including HPA axis suppression and linear growth retardation, due to their higher ratio of skin surface area to body mass. Caution is also advised in individuals with impaired liver function, as reduced clearance may increase systemic exposure to the drug's components.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from topical application of Dexoderm Cream is unlikely due to the low degree of systemic absorption. However, application of excessive amounts, over large areas of skin, or for a prolonged duration, particularly with combination products containing a potent corticosteroid, may increase the risk of systemic side effects.

Overdose Manifestations

Symptoms associated with potential overdose and systemic absorption of the corticosteroid component may include bone weakness, elevated blood pressure, weight gain, and hair loss. Local application site reactions such as swelling, severe itching, burning, and irritation may also be exacerbated by overuse.

Emergency Action and Medical Attention

In the event that you accidentally apply more cream than necessary, the procedural instruction is to gently wash off the excess with water or wipe it away with tissue or cotton. If the medicine is accidentally ingested, immediate medical intervention is required. Promptly consult a doctor if you suspect an overdose, if symptoms persist or worsen, or if you experience any signs of a serious allergic reaction, such as rash or swelling, as this requires immediate medical attention.

Therapeutic Uses of Dexoderm Cream

What Dexoderm Cream Treats: Main Uses and Benefits

Dexoderm Cream's therapeutic role is applied in contexts where additional symptomatic support is needed for skin conditions presenting with systemic or localized discomfort. Topical corticosteroids are generally indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; in cases where concomitant skin infections are present, an appropriate anti-infective agent is utilized.


Key Therapeutic Focus

The cream is commonly used across conditions presenting with acute episodes of severe skin inflammation and applied in areas where short-term symptom management is appropriate. It is generally applied when patients experience pronounced symptoms related to inflammatory or irritative states, such as severe redness (erythema), swelling (edema), and particularly intense itching (pruritus), which may interfere with daily functioning. This is relevant in afflicted areas like infected dermatitis and severe cases of ringworm (Tinea corporis) or jock itch (Tinea cruris) when these have become highly inflamed. The product's composition generally contributes to easing the overall symptom load by addressing these complex manifestations and supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Polymicrobial Dermatoses
Primary Symptoms Eased Severe inflammation, intense itching, redness, swelling.
Conditions Relevant Infected dermatitis, inflamed Tinea infections.
Patient Benefit Supports stability and comfort during symptomatic periods.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dexoderm Cream

The eligibility profile for this Quadruple-Action Cream is strictly governed by regulatory documentation, primarily due to the inclusion of a potent corticosteroid (Clobetasol Propionate).

Classification Rule
Populations for whom use is allowed Adults and adolescents ge 12 years of age are the principal populations for whom use is established.
Populations for whom use is contraindicated Individuals with hypersensitivity to any component (Clobetasol Propionate, Ofloxacin, Ornidazole, Terbinafine Hydrochloride) or related drug classes. Children under one year of age.
Condition-specific contraindications Use is prohibited in the presence of Rosacea, Acne Vulgaris, Perioral Dermatitis, Pruritus without Inflammation, and Viral Skin Infections (e.g., Herpes simplex, Varicella zoster).
Age-related eligibility rules The medicine is not recommended for use in children under 12 years of age.
Pregnancy and lactation eligibility Use with caution in pregnancy and lactation. Application to the breast area must be avoided during breastfeeding.

Official Eligibility Statements:

  • The use of this cream is explicitly prohibited for infants under one year old.
  • Application must be restricted or avoided in high-absorption areas, including the face, groin, and axillae.
  • Patients with hepatic or renal impairment must use the medicine with caution due to the potential for increased systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dexoderm Cream's regulatory interaction profile addresses the systemic potential of its four active agents. A strict restriction requires that alcohol must not be ingested during treatment with the Ornidazole component or for at least three days following discontinuation. Co-administration of the Ofloxacin component with metal cation preparations, such as antacids or iron supplements, is subject to a mandatory two-hour separation rule to prevent a documented reduction in absorption.

Pharmacokinetic interactions are officially noted, including the risk that strong CYP3A4 inhibitors (like Ritonavir) may increase the systemic exposure of the potent corticosteroid component. Separately, the Terbinafine component is documented to inhibit the CYP2D6 enzyme and the clearance of Caffeine.

Significant pharmacodynamic risks are recognized, such as the increased risk of tendinitis and tendon rupture resulting from the fixed combination of the fluoroquinolone and corticosteroid agents. Furthermore, both anti-infective components require caution with Warfarin and other oral anticoagulants due to the potential for increased coagulation results. These regulatory constraints define a profile that emphasizes careful assessment of concurrent systemic medicines.

Mechanism of Action

The glucocorticoid component, dexamethasone, functions as an agonist of the cytosolic glucocorticoid receptor (GR). The lipophilic dexamethasone molecule enters target cells, binds the inactive GR, and induces a conformational change, leading to the dissociation of chaperone proteins.

The activated ligand-receptor complex translocates into the nucleus, binding to specific DNA sequences known as glucocorticoid response elements (GREs), thereby modulating gene transcription (transactivation). This genomic action upregulates the expression of anti-inflammatory proteins, such as Annexin A1 (Lipocortin-1). Annexin A1 inhibits the enzyme phospholipase A2 (PLA2), which is responsible for releasing arachidonic acid from membrane phospholipids.

Blocking PLA2 activity results in a downstream cascade, suppressing the synthesis of pro-inflammatory lipid mediators, including prostaglandins and leukotrienes. Additionally, the GR complex directly represses the transcription (transrepression) of genes encoding numerous inflammatory cytokines (e.g., IL-1, TNF-alpha) and adhesion molecules, inhibiting leukocyte recruitment and stabilizing mast cell membranes. These molecular events result in a system-level physiological modulation characterized by reduced vascular permeability, decreased immune cell migration, and suppressed inflammatory mediator synthesis.

Dosage and Administration Information

How to Use Dexoderm Cream: Official Administration Guidelines

Dexoderm Cream is a Fixed-Dose Combination (FDC) designed for Topical administration, and its usage is subject to the constraints applied to its most potent component, Clobetasol Propionate. Standard administration guidelines define the limits of application to mitigate the potential for systemic exposure.


Official Usage Principles

Instruction Guideline
Route of Administration External use only, applied topically to the affected skin area.
Dosing Schedule & Limit A thin layer is applied and gently rubbed in. The total weekly quantity must not exceed 50 grams, which is the prescribed limit for the potent corticosteroid component.
Dosing Frequency The cream is typically applied twice daily (BID).
Course Duration Treatment is generally limited to 2 consecutive weeks. Use beyond this period is not recommended and requires a clinical reassessment.

Administration Constraints

Standard application protocols specify several procedural conditions essential for proper use. The cream must not be used on the face, groin, or underarms (axillae), and application to the eyes or mucous membranes must be avoided. Furthermore, the treated area should not be covered, bandaged, or wrapped (occlusion), as this significantly increases the absorption of the active ingredients. Use in children under 12 years of age is not recommended due to heightened risk of systemic effects. These procedural constraints ensure that use remains strictly within the intended short-term, high-potency topical context.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dexoderm Cream

Evidence for Use in Mixed Inflammatory Skin Conditions

Dexoderm Cream is a combination product, and research into the specific quadruple formulation primarily involves observational analyses and data collected after the product became available, known as post-marketing reports. This research was conducted during periods of increased symptom activity and was used in research exploring how symptoms change over time in study groups using the cream for conditions characterized by fluctuating or episodic manifestations—specifically, severe skin inflammation accompanied by a presumed mix of fungal, bacterial, or protozoal infection.

The available data show patterns related to changes in symptom scores in the observed populations during the defined treatment interval, tracking physical discomfort such as the intensity of redness (erythema), swelling (edema), and intense itching (pruritus). What remains uncertain is the need for large-scale, independent Randomized Controlled Trials (RCTs) designed specifically for this four-agent cream. Follow-up durations were typically limited to the short course of the steroid component (usually 1–2 weeks), meaning that long-term effects are not fully established.


Rationale from Component Studies: Anti-Inflammatory Action

Research explores the potent corticosteroid component, Clobetasol Propionate, in its monotherapy use for conditions often characterized by severe inflammatory states. Extensive RCTs and systematic reviews on this agent focus on outcomes related to systemic imbalance, such as the reduction of lesion severity. Findings describe patterns observed in the studies as they related to outcomes linked to inflammatory states, contributing to the evidence base for its anti-inflammatory role. These results, however, apply only to the monotherapy product and do not directly reflect the profile of the component when combined with the three anti-infective agents.

Rationale from Component Studies: Anti-Infective Coverage

Evidence for the three anti-infective agents (Ofloxacin, Ornidazole, and Terbinafine) is derived from controlled trials and laboratory studies focused on single-agent use against specific pathogens. This research is part of the exploration into how these components were designed to address a potential polymicrobial infection. Findings provide insight into the action of the individual components against their intended targets. However, this evidence does not determine whether the four active ingredients, when mixed together, have the same effect or whether they interact against an actual mixed infection in a clinical setting.


Research Gaps and Uncertainties

The key research gap lies in the evaluation of the quadruple Fixed-Dose Combination (FDC) as a single therapeutic unit. The results apply only to the populations studied (primarily adults) and do not determine whether an individual will respond similarly. There is limited information on the long-term outcomes and potential consequences of using this multi-component cream. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Clobetasol Propionate Cream, 0.05% Prescribing Information (DailyMed)
  2. Efficacy and Safety of Terbinafine 1% Solution in the Treatment of Interdigital Tinea Pedis and Tinea Corporis or Tinea Cruris

Frequently Asked Questions (FAQ)

Common questions about Dexoderm Cream (FAQ)


Q: Do I need a prescription to get Dexoderm Cream?

Yes, official regulatory databases classify this medicine as a prescription-only drug (Rx). This classification is due to the potent topical corticosteroid component, Clobetasol Propionate.


Q: Is Dexoderm Cream the same as other steroid creams I have used?

No, Dexoderm Cream is officially classified as a Fixed-Dose Combination (FDC) product. This means it combines a potent corticosteroid with three anti-infective agents: an antibiotic, an antiprotozoal, and an antifungal. Most steroid creams you may have used are single-agent products, making this a distinct formulation.


Q: What kind of skin conditions is Dexoderm Cream usually approved for?

Official information indicates this cream is used to manage inflammatory skin conditions, such as infected eczema or dermatitis, when they are complicated by secondary infections. The combination is designed to reduce redness, swelling, and itching while addressing presumed mixed bacterial and fungal pathogens.


Q: Can Dexoderm Cream cause weight gain?

Regulatory documents state that systemic absorption of the potent corticosteroid component is a possibility, especially with extensive use. This can potentially lead to endocrine disorders like Cushing's syndrome, which may include symptoms such as weight gain.


Q: What should I do if my condition doesn't seem to improve with Dexoderm Cream?

If your condition does not show signs of improvement within the typically prescribed treatment duration (usually two weeks), the official guidance recommends discontinuing use. A medical reassessment of the diagnosis should be sought to review the treatment plan.


Q: What does the research say about the effectiveness of Dexoderm Cream for eczema?

The cream is indicated for use in managing inflammatory conditions like infected eczema or dermatitis that are complicated by secondary infections. Studies related to the anti-inflammatory component (Clobetasol) support its role in reducing symptoms such as redness, itching (pruritus), and swelling in these conditions.


Q: What are the signs that I should stop using Dexoderm Cream?

Official warnings state that use should be stopped immediately if you experience signs of a severe allergic reaction, such as facial swelling or difficulty breathing. Discontinuing use and consulting a healthcare provider is recommended if local symptoms like irritation, burning, or redness become significantly worse.


Q: How long does the effect of one application of Dexoderm Cream last?

The official dosing frequency is typically twice daily. While the exact duration of action for a single application is not precisely specified in regulatory documents, this dosing schedule is designed to ensure continuous presence of the active ingredients, suggesting a reapplication interval of approximately 12 hours.


Q: Why does Dexoderm Cream sometimes cause changes in skin color?

Changes in skin color, including skin lightening (hypopigmentation), are known potential local side effects associated with the prolonged use of potent topical corticosteroids like Clobetasol Propionate. These effects can appear in the treated area.


Q: What should I do if I accidentally get Dexoderm Cream in my eye?

Regulatory safety advice specifies that contact with the eyes must be avoided. If accidental exposure occurs, the area should be rinsed thoroughly with water immediately. Consultation with a healthcare provider is advised if irritation, pain, or discomfort persists afterward, due to the risk of conditions like glaucoma.


Q: What percentage of the medication is typically absorbed into the body when applied?

According to official pharmacokinetic data, systemic absorption (entry into the bloodstream) is generally considered low when the cream is applied to intact skin for short periods. However, absorption is highly variable and may increase significantly if the skin barrier is compromised, if large areas are treated, or if the cream is used for long durations.


Q: How quickly can I expect Dexoderm Cream to start helping?

Official efficacy data does not provide a precise time for the onset of action. However, based on the short duration of treatment, signs of improvement in the severe inflammation and associated symptoms should generally begin to appear within the first two weeks of use.


Q: Will Dexoderm Cream interact with my moisturizer or sunscreen?

Official information suggests consultation with a healthcare provider before applying other products like moisturizers or sunscreens to the treated area. Layering products may potentially alter the absorption rate of the active ingredients or affect their intended efficacy.


Q: What happens if I forget to apply a dose of Dexoderm Cream?

If an application is missed, applying the forgotten dose upon remembering is a common instruction. However, if it is almost time for your next scheduled dose, the regulatory guidance is to skip the missed one entirely. Applying a double dose to compensate for a missed dose is not advised.


Q: Why is the core ingredient in Dexoderm Cream sometimes described as 'medium-potency'?

The corticosteroid in this cream is Clobetasol Propionate, which is officially classified by regulatory bodies as a potent or 'super-high' strength topical corticosteroid. The official product documents do not classify the corticosteroid component as medium-potency.


Q: Can Dexoderm Cream affect blood sugar levels in people without diabetes?

Regulatory warnings state that systemic absorption of the potent corticosteroid component carries the potential to cause hyperglycemia (elevated blood sugar levels). This is a risk that may affect individuals even if they do not have a pre-existing diagnosis of diabetes.


Q: Is it safe to use Dexoderm Cream with medicated shampoos?

Official guidance suggests consultation with a healthcare provider before applying other medicated topical products, such as medicated shampoos, near or on the treated area. This is to ensure that the combination does not cause unknown interactions or increase the risk of systemic absorption.


Q: Does Dexoderm Cream cause rebound symptoms if stopped suddenly?

Regulatory warnings primarily focus on the risk of HPA axis suppression (adrenal insufficiency) if a potent topical corticosteroid is stopped abruptly after prolonged or extensive use. The guidance for short-term use is based on managing this systemic safety concern, not a 'rebound' rash.


Q: Can Dexoderm Cream be used on cuts or open wounds?

No, official administration constraints describe that the medicine is not for use on broken, wounded, or compromised skin. Applying the cream to such areas increases the potential for systemic absorption of the active ingredients and the risk of adverse effects.


Q: Can I apply makeup or other cosmetics over Dexoderm Cream?

Official guidance suggests consultation with a healthcare provider before applying any other skin preparations, including makeup or cosmetics, over the treated area. This is to ensure that the ingredients do not cause an unintended interaction or increase the systemic absorption of the medication.


Q: What are the known interactions between Dexoderm Cream and other topical prescription products?

Official information advises caution regarding the co-administration of this cream with other topical prescription products. Consultation with a healthcare provider is generally advised to prevent possible unknown interactions or an undesirable increase in the overall systemic absorption of the active components.


Q: Can applying Dexoderm Cream lead to feelings of nervousness or anxiety?

In rare cases, systemic absorption that results in endocrine disorders (like HPA axis suppression) may be associated with symptoms that include changes in mood. Such effects could potentially manifest as feelings of nervousness or anxiety.

How should Dexoderm Cream be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory information outlines specific conditions required to maintain the stability and safety of Dexoderm Cream.

Storage Conditions:

  • Temperature: Store the cream below 30 C (or below 25 C for some formulations) in a cool and dry location.
  • Protection: Protection from environmental factors is mandatory; do not freeze the medicine, and avoid exposure to heat, moisture, and direct sunlight.
  • Container Integrity: Keep the medicine in its original packaging, and ensure the container or tube is tightly closed after each use to prevent contamination.
  • Safety: The product must be stored out of the sight and reach of children and pets to prevent unauthorized access.

Disposal:

  • Unused or expired medicine must be disposed of properly according to instructions provided on the product label or by local regulations.
  • Ensure that the discarded product is not consumed by children or pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dexoderm Cream found in:

A-Z Index: